|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Jounce Therapeutics, Inc.
| | | Year Established: | 2012 | Ticker: | JNCE | Exchange: | NASDAQ | Main Contact: | Richard Murray, Ph.D., President & CEO | | Other Contacts: | Allison Nance, VP, RA & QA Anna L. Barry, Ph.D., J.D., Senior VP, Legal Stephen Farrand, Ph.D., CTO Kim Drapkin, CPA, CFO Elizabeth Trehu, M.D., CMO Deborah Law, D. Phil., CSO
| | Company Description | Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long?lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial. | |
|
|
|
|
|